Annual Shareholders Equity
$51.10 M
-$22.95 M-30.99%
31 December 2023
Summary:
X4 Pharmaceuticals annual stockholders equity is currently $51.10 million, with the most recent change of -$22.95 million (-30.99%) on 31 December 2023. During the last 3 years, it has fallen by -$13.31 million (-20.67%). XFOR annual shareholders equity is now -60.46% below its all-time high of $129.22 million, reached on 31 December 2019.XFOR Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Shareholders Equity
$59.62 M
-$34.83 M-36.88%
30 September 2024
Summary:
X4 Pharmaceuticals quarterly stockholders equity is currently $59.62 million, with the most recent change of -$34.83 million (-36.88%) on 30 September 2024. Over the past year, it has increased by +$8.52 million (+16.68%). XFOR quarterly shareholders equity is now -53.86% below its all-time high of $129.22 million, reached on 31 December 2019.XFOR Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XFOR Shareholders Equity Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | +16.7% |
| 3 y3 years | -20.7% | -7.4% |
| 5 y5 years | -60.5% | -53.9% |
XFOR Shareholders Equity High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -31.0% | at low | -36.9% | +5654.9% |
| 5 y | 5 years | -60.5% | at low | -53.9% | +5654.9% |
| alltime | all time | -60.5% | +190.3% | -53.9% | +205.4% |
X4 Pharmaceuticals Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $59.62 M(-36.9%) |
| June 2024 | - | $94.45 M(+9016.9%) |
| Mar 2024 | - | $1.04 M(-98.0%) |
| Dec 2023 | $51.10 M(-31.0%) | $51.10 M(-24.4%) |
| Sept 2023 | - | $67.59 M(+0.1%) |
| June 2023 | - | $67.53 M(+30.7%) |
| Mar 2023 | - | $51.68 M(-30.2%) |
| Dec 2022 | $74.05 M(+15.0%) | $74.05 M(+19.7%) |
| Sept 2022 | - | $61.85 M(+105.7%) |
| June 2022 | - | $30.07 M(-39.5%) |
| Mar 2022 | - | $49.71 M(-22.8%) |
| Dec 2021 | $64.41 M(-11.5%) | $64.41 M(-6.2%) |
| Sept 2021 | - | $68.68 M(-23.0%) |
| June 2021 | - | $89.21 M(-16.6%) |
| Mar 2021 | - | $106.94 M(+46.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2020 | $72.80 M(-43.7%) | $72.80 M(-18.8%) |
| Sept 2020 | - | $89.71 M(-14.5%) |
| June 2020 | - | $104.88 M(-11.7%) |
| Mar 2020 | - | $118.79 M(-8.1%) |
| Dec 2019 | $129.22 M(+498.2%) | $129.22 M(+63.3%) |
| Sept 2019 | - | $79.11 M(-17.7%) |
| June 2019 | - | $96.17 M(+226.6%) |
| Mar 2019 | - | $29.44 M(+36.3%) |
| Dec 2018 | $21.60 M(-63.2%) | $21.60 M(-22.6%) |
| Sept 2018 | - | $27.90 M(-26.1%) |
| June 2018 | - | $37.76 M(-22.0%) |
| Mar 2018 | - | $48.42 M(-17.5%) |
| Dec 2017 | $58.71 M(-203.8%) | $58.71 M(+406.1%) |
| Sept 2017 | - | $11.60 M(-120.5%) |
| Dec 2016 | -$56.56 M(+64.8%) | -$56.56 M |
| Dec 2015 | -$34.32 M | - |
FAQ
- What is X4 Pharmaceuticals annual stockholders equity?
- What is the all time high annual shareholders equity for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for X4 Pharmaceuticals?
- What is X4 Pharmaceuticals quarterly shareholders equity year-on-year change?
What is X4 Pharmaceuticals annual stockholders equity?
The current annual shareholders equity of XFOR is $51.10 M
What is the all time high annual shareholders equity for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high annual stockholders equity is $129.22 M
What is X4 Pharmaceuticals quarterly stockholders equity?
The current quarterly shareholders equity of XFOR is $59.62 M
What is the all time high quarterly shareholders equity for X4 Pharmaceuticals?
X4 Pharmaceuticals all-time high quarterly stockholders equity is $129.22 M
What is X4 Pharmaceuticals quarterly shareholders equity year-on-year change?
Over the past year, XFOR quarterly stockholders equity has changed by +$8.52 M (+16.68%)